Houston, TX -- (SBWIRE) -- 03/22/2013 -- AnotherWinningTrade.com offers its daily alerts and market content newsletter to investors looking for the best information available! AnotherWinningTrade.com provides its subscribers with useful, timely information and exclusive alerts on penny stocks, mid cap stocks and large cap stocks with the potential to deliver gains of 100%-200% or more. We have the top alerts in the industry. To receive our FREE, comprehensive newsletter, visit AnotherWinningTrade.com.
Tibco Software Inc.(NASDAQ:TIBX) lost 13.68% and is trading at $20. TIBCO Software Inc. (TIBCO) is a provider of middleware and infrastructure software. The Company’s standards-based software platform enables customers to create flexible, event-driven applications from infrastructure and deliver real-time, actionable insights.
How Should Investors Trade TIBX After The Solid Jump? Let’s Find Out Here
Arbor Realty Trust, Inc.(NYSE:ABR) is lower 6.93% and is trading at $7.66. Arbor Realty Trust, Inc. is a specialized real estate finance company. The Company invests in a diversified portfolio of structured finance assets in the multi-family and commercial real estate markets.
Is ABR Ready To Jump Again After The Solid Momentum? Get Free Trend Analysis Here
Informatica Corporation(NASDAQ:INFA) fell 5.86% and is trading at $33.76. Informatica Corporation (Informatica) is an independent provider of enterprise data integration and data quality software and services. The Company's software solutions enable a variety of complex enterprise data integration initiatives through the technologies, which include enterprise data integration, data quality, master data management, business to business (B2B) data exchange, application information lifecycle management, complex event processing, ultra messaging, and cloud data integration.
Is INFA Buy After The Recent Price Movement? Find Out Here
Pharmacyclics, Inc.(NASDAQ:PCYC) is lower 5.45% and is trading at $76.16. Pharmacyclics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.
Is PCYC a Buy At The Current Market Price? Don’t Miss Out Our Special Coverage Here
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.
Winning Media LLC
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)